ATS PC Assembly

[ATS PC Assembly @ATS_PC]

New #PCTweetorials: PH Patient Perspectives 🫁 Diagnosis can take years, and fear, uncertainty, and treatment burden are as central to patients' stories as PVR and 6MWD. Time we listened — reading list below 👇 #PHAware #PulmonaryHypertension #MedEd

[Naomi Habib @NaomiHabib]

Expert Insights, from Guidelines to the Real World: The incidence of PVOD found in BOTH scleroderma PH-ILD and scleroderma PAH is high (from lung explant study at https://t.co/gIr0wctWCU). #CHEST2026 #CHESTSoMe @accpchest @CHESTPulmCardio @SandeepSahayMD

[Naomi Habib @NaomiHabib]

Expert Insights, from the Data to the Real World: Pregnancy in PAH—confirmation of hemodynamics, optimization of PH therapy, and COUNSELING throughout! #CHEST2026 #CHESTSoMe @accpchest @CHESTPulmCardio

[Naomi Habib @NaomiHabib]

Expert Insights, from Data to Real World: POPH — Can be due to portal hypertension, cirrhotic or non-cirrhotic. Pay close attention to hemodynamics, an otherwise “normal” CO is often relatively low for portal hypertension patients who usually have hyperdynamic CO at baseline. #CHEST2026 #CHESTSoMe @accpchest @CHESTPulmCardio

[Dr Sarang Patil, MD, ATSF, FCCP @sarangspatil1]

💡 High-yield POCUS algorithm for acute Right Ventricular Failure from #CHEST2026:
Key diagnostic checkpoints at the bedside:

🔹 RV:LV ratio ≥1.0 (Apical 4-chamber)
🔹 Septal flattening / D-shaped LV in PSAX (pressure/volume overload)
🔹 Reduced TAPSE (< 1.7 cm) & RV free wall S' (< 9.5 cm/s})
🔹 Dilated IVC (> 2.1 cm) with < 50% collapse

Integrate these findings early when managing shock!

#DrSarangPatil #CHEST2026 #POCUS #CriticalCare #CardioPulm

[ATS PC Assembly @ATS_PC]

👋Don't forget to tag us at @ats_pc about all the #PH #PVD #PERT action while you're at #CHEST2026! We're all one community! 🫁🫀🌎 @accpchest @CHESTPulmCardio @atsearlycareer

[The Pulmonary Vascular Research Institute @PVRI]

📢 Just one week to go!

8th International Leh Symposium 2026
📍 McLeod Ganj, Dharamshala, India
🗓 23-27 October 2026

Join the global PH community to explore the latest research on therapeutic targets and molecular mechanisms for pulmonary diseases in hypoxia.

Highlights include:
▪️cutting-edge science in hypoxia and pulmonary disease
▪️international experts in research and clinical care
▪️opportunities for collaboration and scientific exchange
▪️discussions on advancing prevention and treatment strategies

➡️ Register here: https://t.co/Ag2N6yl7Ch

[The Pulmonary Vascular Research Institute @PVRI]

Who do you think would make an excellent PVRI President? 🏆💡 Nominations are open for two more weeks for PVRI President 2028-30 and for PVRI Achievement Awards 2026.

Help us celebrate the people shaping PH research, care & collaboration around the world. ➡️ Nominate: https://t.co/HAnPdBoTBh

Nominations close: 28 October, 09:00 GMT

[CHEST @accpchest]

In recognition of World Thrombosis Day on October 13, CHEST joins the global effort to raise awareness of thrombosis and its prevention.
Explore a special feature from journal CHEST® reviewing key recommendations for antithrombotic therapy in venous thromboembolism (VTE) from three CHEST guidelines.
Read more: https://t.co/qVCeWnf5Qz

[ATS PC Assembly @ATS_PC]

#ThePeoplesVentricle

[CHEST @accpchest]

The latest CHEST How I Do It focuses on the management of acute decompensated right ventricular failure in patients with known pulmonary arterial hypertension.

Read the article in the October issue of the journal CHEST®: https://t.co/YTJxPtg4gZ
#MedEd #JournalCHEST

[The Pulmonary Vascular Research Institute @PVRI]

What can blood biomarkers tell us about PAH? 🩸

Blood Biomarkers in Pulmonary Arterial Hypertension – New Insights
📅 12 November 2026
🕓️ 16:00 - 17:00 GMT

You'll hear the latest research on:
▪️biomarker validation for clinical use
▪️plasma proteome risk stratification
▪️NOTCH3-ECD as a biomarker for PAH
▪️novel predictors of outcomes in PAH
▪️markers of vascular dysfunction

➡️ Register now: https://t.co/UJFgIVd6Gj

[ATS PC Assembly @ATS_PC]

What an awesome resource for all the #CHEST2026 attendees! 👇👀🗓️

[Francisco Soto, MD, MS, MBA @FSotoMD]

Attending #CHEST2026 and interested in cardiac and pulmonary vascular disease?

See the entire list of PVD/CV sessions in one place 👇

Curated guide to pulmonary hypertension, pulmonary embolism, cardiovascular and cardiac ICU content, research activities, and other key CV and PVD-focused sessions.

Many thanks to our stellar PVD Section fellows,
#Romina Gomez and #Laura Saldivar, for compiling this valuable resource on behalf of @accpchest and the @CHESTPulmCardio Network

🌵 🌵 🌵 🌵

#CHEST2026 Phoenix, AZ October 18-21, 2026

@ATS_PC
@PHAssociation
@PVRI
@ALATorax

[ATS PC Assembly @ATS_PC]

We can't wait for this PHantastic session at #CHEST2026! 👇
@FSotoMD @ParthRali @CHESTPulmCardio @accpchest

[Francisco Soto, MD, MS, MBA @FSotoMD]

Friend: "I still struggle managing pulmonary hypertension if the disease doesn't follow the guidelines"

Me: "Aren't you going to CHEST 2026 in Phoenix?"

Friend: "Yes! Why?"

Me: "Say no more!"

The @accpchest and its @CHESTPulmCardio have assembled a session just for you:

"Guidelines vs Real-Life Expert Decisions in Pulmonary Hypertension Treatment: A Conversation With Experts"

🌵🌵🌵🌵

Six legendary PH authorities will ride into town to track down the "WANTED" PH cases that keep us up at night.

Dr. Rali and I will present them with six such case scenarios and will have them answer the tough questions.

Check the attached flier and join us Sunday, October 18, 1:30 PM, at the 📍 Phoenix Convention Center, North Building, Room 226 A

Ride in early and claim your seat. Or you may be left outside eating Arizona dust!

#CHEST2026
#pulmonaryhypertension

@ParthRali
#OksanaShlobin
#JessicaHuston
@melendres_lana
@SandeepSahayMD
@AnnaHemnes
@hilarydubrockMD

@PVRI
@PHAssociation
@ATS_PC

[ATS Early Career @atsearlycareer]

Got an idea for #ATS2027?
We're seeking proposals for the ATS Networking Super Center Learning Studio! Submit ideas for networking events, interactive workshops, presentations, or small-group discussions.
#CareerDevelopment

Submit a proposal today: https://t.co/Nt99LzBliM

[CHEST @accpchest]

INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (October 8): What factors are associated with higher mean pulmonary arterial pressure after balloon pulmonary angioplasty?

Read the original research in the October issue of the journal CHEST®: https://t.co/oAt0q50eDb
#MedEd #JournalCHEST

[ATS PC Assembly @ATS_PC]

We couldn't agree more with Dr. @RaedDweikMD! Here's a little plug to keep an eye out for our annual #PracticalPH podcast where we preview all the @ATS_PC sessions and talk about how to navigate the ATS International Conference.

Throwback to #ATS2026: https://t.co/NlarKswybq

[American Thoracic Society (ATS) @atscommunity]

What can you get out of attending the ATS International Conference? On the ATS Breathe Easy podcast, ATS immediate past-president @RaedDweikMD, MD, MBA, ATSF, explains all of the benefits he has received throughout his career by attending the annual meeting.

Watch the full episode on ATS NOW or tune in wherever you listen to podcasts: https://t.co/7sr0R7YYBh

[ATS Early Career @atsearlycareer]

We are recruiting for ECP teachers!
ATS is seeking volunteers to teach at the ATS 2027 Early Career Professional (ECP) Programs in New Orleans, May 14-15, 2027
📅Apply by October 30, 2026
✉️Assignments will be emailed in January 2027
👉Interested? https://t.co/ncmlspbk4s

[Kurt Prins @kurt_prins]

Ecstatic to share our latest work in @CircRes aimed at understanding RV dysfunction. Multi-omics analyses nominated underexplored pathways in severe RV dysfunction. https://t.co/C8I0wdjVrK. @Jenna_Mendelson @MadelynJBlake @MUSC_IM @PVRI @ATS_PC

[ATS PC Assembly @ATS_PC]

📣🌟It's time for a boost of inspiration from another @atsearlycareer star! Featuring Dr. Gabriel Altit @CardioNeo, who studies pulmonary vascular health after preterm birth. 👏 @atscommunity

[The PERT Consortium® @PERTConsortium]

In the Top PE Papers session, Dr. @GregoryPiazza4 presents the results of the exciting #HIPRO trial, showing that low-dose apixaban reduced the rate of recurrent VTE at 12 months in patients with provoked VTE #pert2026

[The PERT Consortium® @PERTConsortium]

We’re fortunate to have several new studies from 2025 helping inform our decisions on extended-duration, reduced-dose DOACs in higher-risk VTE populations, where balancing recurrence and bleeding risk remains critical. #PERT2026